文献速递消化道肿瘤放疗放疗物理与技术

腹部消化道恶性肿瘤再程放疗的国际系统综述:ReCOG协作组临床实践总结

Reirradiation clinical practice in gastrointestinal abdominal malignancies: an international reirradiation collaborative group (ReCOG) systematic review.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-08-13

再程放疗剂量、分割和剂量限值差异很大,仅半数研究报告了明确危及器官限值;汇总加权中位总生存期为19.6个月,1年局部控制率19%–93%,严重(≥3级)毒性多报告为5%–15%。

要点

  • 腹部再程放疗在部分患者中可获得有意义的局部控制和生存。
  • 再程放疗的剂量、分割和危及器官限值报告异质性大,仅半数研究明确限值。
  • 严重毒性多报告为5%–15%,但肝脏再程放疗有研究报道25%致死性RILD。

核心结论

  • 腹部恶性肿瘤再程放疗在选定患者中似可获得有意义的局部控制和生存。
  • 计划、剂量和毒性报告的异质性仍是建立最佳实践的主要挑战。
  • 需要标准化报告剂量、限值和剂量-体积关系以指导安全有效的再程放疗。

研究设计与样本

  • ReCOG多学科团队按PRISMA框架系统检索Cochrane Central、CINAHL Plus、EMBASE和PubMed截至2024年8月30日的文献。
  • 每项研究报告患者数中位数为26例(范围2–245例)。
  • 提取患者特征、放疗剂量、剂量限值、治疗结果和毒性数据,并在可行时进行汇总加权分析。

主要发现

  • 报告的肿瘤部位中,718例为肝脏肿瘤、277例为胰腺肿瘤,另有较少混合/淋巴结靶区。
  • 再程放疗剂量、分割方案和剂量限值差异很大,仅半数研究提供了明确的危及器官限值。
  • 3项研究纳入了姑息治疗意图的患者。
  • 中位总生存期范围为5.9至44个月,20项报告该指标的研究汇总加权中位OS为19.6个月。
  • 1年局部控制率范围为19%至93%,严重(≥3级)毒性通常报告为5%–15%,但一项研究报告肝脏再程放疗中25%致死性RILD。

关键数值与推荐

  • 再程放疗剂量、分割方案和剂量限值在纳入研究中差异很大,仅半数研究提供明确危及器官限值。
  • 汇总加权中位总生存期为19.6个月(基于20项报告该指标的研究)。
  • 1年局部控制率范围为19%至93%。
  • 严重(≥3级)毒性通常报告为5%–15%,一项研究报告25%致死性RILD。

临床怎么用

  • 腹部再程放疗可用于选定患者以实现局部控制和生存获益。
  • 治疗计划中应明确报告危及器官限值、剂量和分割方案。
  • 需关注肝脏再程放疗的致死性RILD风险,并标准化毒性报告。

局限性

  • 每项研究患者数中位数仅26例(范围2–245例),样本量有限。
  • 再程放疗剂量、分割和剂量限值报告异质性大,仅半数研究提供明确危及器官限值。
  • 毒性报告方式不一致,限制了最佳实践的建立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Reirradiation in abdominal malignancies has grown more common with advanced radiotherapy techniques. However, clinical use and implementation varies, and there remains limited consensus on best practices for reirradiation. In this systematic review, a multidisciplinary team treating gastrointestinal and hepatobiliary malignancies within the Reirradiation Collaborative Group (ReCOG) convened to review published literature on reirradiation in the abdomen to offer insights into patient selection, radiotherapy planning, risk management, and assessing knowledge gaps for future development of guidelines. METHODS AND MATERIALS: A systematic search of Cochrane Central, CINAHL Plus, EMBASE, and PubMed up to August 30, 2024, was conducted as per Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) framework. Data on patient characteristics, radiation doses, dose constraints, treatment outcomes, and toxicities were extracted. Where feasible, pooled weighted analyses were performed. RESULTS: Thirty-three studies involving 1,264 patients met inclusion criteria: 30 were retrospective and 3 prospective. The median number of patients reported per study was 26 (range 2-245). Of the reported tumor sites, 718 patients had liver tumors and 277 pancreas, with smaller numbers of mixed/lymph node targets. Reirradiation doses, fractionation schemes, and dose constraints varied widely; only half of the studies provided explicit organ-at-risk constraints. Three studies included patients treated with palliative intent. Median overall survival ranged from 5.9 to 44 months, with a pooled weighted median OS of 19.6 months across 20 studies that reported it. One-year local control rates ranged from 19 % to 93 %, with severe (grade ≥ 3) toxicities typically reported in 5-15 % of patients, although one study reported 25 % lethal RILD in liver reirradiation. CONCLUSION: Reirradiation in abdominal malignancies appears to be able to achieve meaningful local control and survival in select patients, though heterogeneity in planning, dosing, and toxicity reporting remains a major challenge for establishing best practices. Standardized reporting of doses, constraints, and dose-volume relationships are needed to guide safe and effective reirradiation in this setting.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Malik NH, Plastaras JP, Corradini S, et al. Reirradiation clinical practice in gastrointestinal abdominal malignancies: an international reirradiation collaborative group (ReCOG) systematic review. Clin Transl Radiat Oncol. 2025. PMID: 40895774. doi:10.1016/j.ctro.2025.101033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。